The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 91 (high attention) · dilution pressure high · listing risk high · governance risk low · runway 7.8 mo · strongest signal: Hearings panel (Aug 11, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (runway 6–12 months) coexists with live selling machinery (atm program, offering (424b)). Base case is a discounted raise; the question is when, not if.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 14, 2026 | ▼ Going-concern language | “going concern periodic” language in 10-Q (10-Q) filed 2026-08-14 filing | 25 |
| Aug 11, 2026 | ▼ Hearings panel | “hearings panel” language in 8-K (8-K) filed 2026-08-11 filing | 59 |
| Aug 11, 2026 | ▼ Exchange deficiency notice | 8-K Item 3.01 filed 2026-08-11 (accepted 16:05 ET) filing | 55 |
| Aug 11, 2026 | ▼ Minimum bid deficiency | “min bid” language in 8-K (8-K) filed 2026-08-11 filing | 48 |
| Aug 11, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (8-K) filed 2026-08-11 filing | 46 |
| Aug 11, 2026 | ▼ Reverse split | “reverse split” language in 8-K (8-K) filed 2026-08-11 filing | 32 |
| Jul 31, 2026 | ▼ Offering (424B) | 424B5 prospectus supplement 2026-07-31; 5 prior 424B filings in 12m filing | 48 |
| Jul 31, 2026 | ▼ ATM program | “atm” language in 8-K (8-K) filed 2026-07-31 filing | 38 |
| Jun 30, 2026 | ▼ Share count +25% | Shares outstanding 19,127,643 (2026-05-14) -> 24,897,581 (2026-08-14), +30% filing | 34 |
| Jun 30, 2026 | ▼ Runway 6–12 months | ~7.8 months runway: liquidity $7,891,911 as of 2026-06-30, burn $12,205,969/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 26 |
VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · screener →